Physician profile
Julia A Abraham
NPI 1417417403
$2,122.03
in general payments reported to CMS, 2019-2025
24 companies · $871 in 2025
The $871 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $110 · 2023: $483 · 2024: $658 · 2025: $871.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,993 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,993.16 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $421.56 | 2022-2025 | Qulipta, Vraylar |
| Glaxosmithkline, LLC. | $284.98 | 2022-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $282.66 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Pfizer INC. | $249.04 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $184.38 | 2023-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $169.04 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $98.69 | 2024-2025 | |
| Amgen INC. | $56.07 | 2022-2025 | Repatha, Otezla, Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.12 | 2025 | Xifaxan |
| Ibsa Pharma INC. | $35.73 | 2024-2025 | Tirosint, Licart, Flector |
| E.R. Squibb & Sons, L.L.C. | $31.71 | 2022-2023 | Camzyos |
| Medtronic, INC. | $31.11 | 2025 | Synchromedii |
| Madrigal Pharmaceuticals | $28.24 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $26.10 | 2023-2024 | |
| Axsome Therapeutics, INC. | $25.37 | 2023 | Sunosi |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $23.16 | 2022 | |
| Philips North America LLC | $22.80 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Otsuka America Pharmaceutical, INC. | $18.90 | 2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.85 | 2025 | Jardiance |
| Ars Pharmaceuticals Operations, INC. | $18.11 | 2025 | Neffy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $15.73 | 2025 | Caplyta |
| Merck Sharp & Dohme LLC | $14.81 | 2023 | Belsomra |
| Exact Sciences Corporation | $14.73 | 2025 | Cologuard Collection Kit |
| Antares Pharma, INC. | $13.14 | 2023 | Tlando, Nocdurna, Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julia Abraham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.